FIELD: biotechnology.
SUBSTANCE: following is presented: a product containing the cofactor of complement factor I (CFI) and complement factor I (CFI) or nucleotide sequences encoding them, in the form of a combination preparation for simultaneous, separate or sequential use in therapy, an isolated polynucleotide encoding the cofactor of complement factor I (CFI) and complement factor I (CFI), an expression vector and host cells that produce the cofactor complement factor I (CFI) and complement factor I (CFI). Also the following is disclosed: a pharmaceutical composition for treating or preventing a complement-mediated ocular disorder, a method of treating or preventing a complement-mediated ocular disorder, and a method of delivering cofactor complement factor I (CFI) and complement factor (CFI) to the eye of a subject.
EFFECT: invention is used for the treatment of eye disorders.
40 cl, 11 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CODON-OPTIMIZED COMPLEMENT FACTOR I | 2019 |
|
RU2824048C2 |
| GENE THERAPY | 2016 |
|
RU2740038C2 |
| TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2017 |
|
RU2768982C2 |
| ANTIBODY TO COMPLEMENT Bb FACTOR | 2015 |
|
RU2673036C2 |
| COMPOSITION AND METHOD FOR TREATING A COMPLEMENT-MEDIATED DISEASE | 2016 |
|
RU2727411C2 |
| ANALOGUES OF COMPLEMENT FACTOR B AND THEIR APPLICATION | 2012 |
|
RU2639521C2 |
| MODIFIED CLOSED CIRCULAR DNA (CCDNA) CONTAINING SYMMETRIC MODIFIED INVERTED END REPEATED SEQUENCES | 2019 |
|
RU2816963C2 |
| MODIFIED CLOSED-ENDED DNA (scDNA) | 2018 |
|
RU2800026C2 |
| ANTIBODIES TO COMPLEMENT COMPONENT C5 | 2015 |
|
RU2693430C2 |
| C3b ANTIBODIES AND METHODS FOR PREVENTION AND TREATMENT OF COMPLEMENT-RELATED DISORDERS | 2008 |
|
RU2473563C2 |
